about
3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat modelPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesT2 relaxation time is related to liver fibrosis severity.Host genetics predict clinical deterioration in HCV-related cirrhosis.Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?Stressing out over survival: glutamine as an apoptotic modulator.Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinomaA functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcomeComparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in miceA functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patientsThe XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through AutophagyMolecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibitionTranscriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells.Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer.Epithelial-to-mesenchymal transition predicts prognosis in clinical gastric cancer.Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells.CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence.Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells.Disease Biomarkers in Gastrointestinal Malignancies.Reply: To PMID 24677197.Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models.Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma.Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model.Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapyGenomic risk of hepatitis C-related hepatocellular carcinomaEpithelial-to-mesenchymal transition predicts prognosis of pancreatic cancerEpigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular CarcinomaAdvanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis
P50
Q27309869-87C240CD-87A1-4A7E-B35B-6E963535C61DQ28272678-9BF8D94A-D651-480B-9B89-F197565D127DQ30383680-1DF58570-259D-49B7-AB61-773592F46E7EQ34689664-AE5B6960-8F37-46DD-ADBB-DFA5039CC314Q36139606-BEC8A8B1-9EED-4BD7-879E-AD9AD3BC862FQ36254208-38A4E1FF-9134-494A-8EBF-BF3E25B6FA3FQ36788544-243923A1-4B7C-4B17-9A0E-45B2F9365E80Q36848514-24C852EF-2FEE-455F-AB5B-883527484E2EQ36948334-81FE9F2D-CAD3-4D2E-A19C-C2D765C02A27Q37132189-687ED56D-2EB6-4815-A897-08F5D67D64A6Q37398922-29BDEA38-6BC2-488A-949E-5F812124C630Q37519318-47B93960-F173-404D-8D17-31776958D3E9Q37631288-640FCF09-1D76-42BF-AF4E-0C3887384EE8Q37678954-DDE6E6A9-53A4-476D-978F-4CE1E35017F4Q38726399-17972C0D-529A-41AD-BF7F-E6466FA0E4BFQ38856822-AEC265F5-4848-4676-8250-7139AF66F9DAQ39031584-C419AE2D-DF85-4699-8E60-71AA4F465B4EQ39996225-7E75762E-08F6-495D-877F-83BA6E3CAB48Q40165263-5794AC60-F97E-4157-BA99-EE6906F7D054Q40625438-7CBA3F97-7447-4C2D-8D2F-0345A2BF6603Q41294963-1DFFD5E0-5651-4B6B-89A3-2CB0096E72B9Q42315013-4BA2B3E2-8902-476A-8D25-A24E0C73A450Q42416485-FD564457-4E61-45E3-9BD8-144DB108FE12Q42976870-B59B228E-BFD7-4BEB-9E47-68BCB44266CFQ48315576-5C7BE737-ED8D-47CC-A647-EE333B489996Q51082980-2DBDC7FD-0A8A-41E4-8B1D-1C2FCC38C060Q51224715-E9482107-4B15-434C-912A-8190C59AC4C6Q54208538-3FE2B67B-2830-4235-B0CD-FED327364C99Q57174120-91726DC6-B122-4DC0-AD18-A394E55DE190Q85026316-932C4640-0144-4223-92F7-1D9BC23D625CQ86054645-94E7DF15-8F9F-4ED4-922C-0CE6490575BCQ91610491-EB2396B1-9CCA-4DA3-B36E-4B8B9A329D8FQ93337209-1D94FA5D-A76F-40FF-8CE2-4003E996B842
P50
description
Forscher
@de
investigador
@es
onderzoeker
@nl
researcher
@en
ricercatore
@it
研究員
@ja
研究者
@zh
name
Bryan C Fuchs
@en
Bryan C Fuchs
@nl
type
label
Bryan C Fuchs
@en
Bryan C Fuchs
@nl
prefLabel
Bryan C Fuchs
@en
Bryan C Fuchs
@nl
P106
P31
P496
0000-0002-2149-3081